Contract Research Outsourcing (CRO), which came into being in the seventies, evolved into an essential component of pharmaceutical market scenario. CRO has emerged as a topic of great interest in the global pharmaceutical and biotechnology markets. Patent expiries, heightened competition in generic drug space, and dwindling drug discoveries necessitate research and development (R&D), innovation, and marketing of new pharma and biotech products to combat price fixing and cost escalations. Smaller product life spans, worldwide regulatory challenges, and the increasingly slim deadlines for clinical development magnify in-house R&D expenditure and affect productivity. The CRO concept emerged as a means to control in-house R&D costs, expand capacities, and improve core skills. Contract research organizations now offer a whole array of expert services ranging from pharmacology, pre-clinical safety evaluation, clinical trial management, study design, statistical analysis, regulatory services, and data collection to product support.

These and other market data and trends are presented in "Contract Research Outsourcing: A Global Market Report" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.